IL-23R
IL-23R Molekülinformation
| Englischer Name | Interleukin 23 Receptor | Anzahl der inverkehr gebrachten Arzneimittel | 1 |
| Anzahl der klinischen Arzneimittel | 2 | Target-Alias | IL-23 receptor，IL23R，Interleukin 23 Receptor，Interleukin-23 Receptor，IL-23R |
| Höchste Forschungs- und Entwicklungsphase | Approved | ||
| Englischer Name | Interleukin 23 Receptor |
| Target-Alias | IL-23 receptor，IL23R，Interleukin 23 Receptor，Interleukin-23 Receptor，IL-23R |
| Anzahl der inverkehr gebrachten Arzneimittel | 1 |
| Anzahl der klinischen Arzneimittel | 2 |
| Höchste Forschungs- und Entwicklungsphase | Approved |
Produktanfrage
IL-23R Molekülhintergrund
Interleukin 23 receptor (IL-23R) is a type I cytokine receptor, and IL-23R pairs with the receptor molecule IL12RB1/IL12Rbeta1, and both are required for IL23A signaling. Also, IL-23R associates constitutively with Janus kinase 2 (JAK2), and binds to transcription activator STAT3 in a ligand-dependent manner. Furthermore, IL-23R mediates T-cells, NK cells and possibly certain macrophage/myeloid cells stimulation probably through activation of the Jak-Stat signaling cascade. As for IL-23, it may be responsible for autoimmune inflammatory diseases and be important for tumorigenesis.
IL-23R Molekülalias
IL-23 R,IL-23 Receptor
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Bezisterim | HE-3286; NE-3107 | Phase 3 Clinical | Harbor Therapeutics Inc | Alzheimer Disease; Arthritis, Rheumatoid; Brain Injuries, Traumatic; Colitis, Ulcerative; Diabetes Mellitus, Type 2; Insulin Resistance; Parkinson Disease; Post-Acute COVID-19 Syndrome | Details |
| PN-232 | PN-232; JNJ75105186 | Phase 1 Clinical | Protagonist Therapeutics Inc | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Icotrokinra | PN-235; JNJ-2113; JNJ-77242113-AAC; PN-21235; JNJ-77242113 | Approved | Protagonist Therapeutics Inc | ICOTYDE | United States | Plaque psoriasis | Janssen Biotech Inc | 2026-03-17 | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Erythrodermic psoriasis; Generalised pustular psoriasis; Plaque psoriasis; Psoriasis | Details |
- Molekülinformation
- Produktanfrage
- Inverkehr gebrachte Arzneimittelinformation
- Klinische Arzneimittelinformation